| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9649364 | XERIS | Methods for producing stable therapeutic formulations in aprotic polar solvents |
Apr, 2036
(12 years from now) | |
| US11590205 | XERIS | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
Apr, 2036
(12 years from now) | |
Gvoke Hypopen is owned by Xeris.
Gvoke Hypopen contains Glucagon.
Gvoke Hypopen has a total of 2 drug patents out of which 0 drug patents have expired.
Gvoke Hypopen was authorised for market use on 10 September, 2019.
Gvoke Hypopen is available in solution;subcutaneous dosage forms.
Gvoke Hypopen can be used as treatment of severe hypoglycemia.
The generics of Gvoke Hypopen are possible to be released after 22 April, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Sep 10, 2022 |
Drugs and Companies using GLUCAGON ingredient
Market Authorisation Date: 10 September, 2019
Treatment: Treatment of severe hypoglycemia
Dosage: SOLUTION;SUBCUTANEOUS
GVOKE HYPOPEN family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic